ARA-290 (Cibinetide)

Erythropoietin, minus the blood

EPO is famous for telling the marrow to make red blood cells, and infamous for the clots and strokes that follow when athletes abuse it. But EPO does something else at a site of injury: it protects and repairs stressed tissue. The problem is you cannot dose EPO for repair without also thickening the blood and taking on that risk.

Michael Brines and Anthony Cerami worked out why the two effects separate. EPO's repair signal runs through a different receptor than its blood signal — a heterocomplex of the EPO receptor joined to the beta-common receptor, which they named the innate repair receptor.

Once repair was known to run through a distinct receptor, they built small peptides mimicking only the repair-active face of EPO. ARA-290 is that idea shipped as an 11-amino-acid drug.

The receptor that only shows up when tissue is hurt

The innate repair receptor is not sitting on healthy cells. It is upregulated on injured and inflamed tissue — so ARA-290 acts where there is damage and stays quiet where there isn't. Its job there is anti-inflammatory and pro-survival: it tells macrophages to stand down and keeps stressed cells alive.

It regrows nerve fibers — measured, not felt

This is what separates ARA-290 from nearly everything else marketed as a healing peptide. In a Phase 2b randomized controlled trial in 64 patients with sarcoidosis-associated small-fiber neuropathy, 4 mg/day cibinetide significantly increased corneal nerve fiber area — an objective, imaged measure — and raised GAP-43-positive regenerating fibers in the skin. GAP-43 marks nerves actively growing back.

An earlier randomized, double-blind pilot had already shown the symptom side: significantly better neuropathy scores versus placebo by week four.

The independent read was blunt: it regenerates nerve fibers.

It calms the nerve, not just the symptom

This is why it matters for a disc. Radicular pain — sciatica — is not only mechanical; when nucleus pulposus contacts a nerve root it sets off neuroinflammation, much of it driven by activated microglia in the spinal cord. In nerve-injury models, ARA-290 produced long-lasting, dose-dependent reductions in allodynia that tracked with suppression of exactly that spinal microglial response.

So the mechanism is not "mask the pain for a few hours." It is "quiet the central inflammation generating the pain" — a more durable kind of relief, aimed at the specific way a herniated disc hurts.

The benefit generalizes past nerves

The repair signal is not nerve-specific. The same peptide class is anti-apoptotic and tissue-protective in the heart.

And a second human population — type 2 diabetics — showed improved neuropathic symptoms alongside better HbA1c and lipids over 56 days, with no safety signal.

Two independent human neuropathy datasets plus organ-level tissue protection in the lab is a stronger evidence base than most peptides in this category can claim.

How it's dosed

The human trials are specific and consistent, which is unusual here.

• Dose: 4 mg subcutaneously, once daily, is the effective and consensus clinical dose. The dose-ranging trial tested 1, 4, and 8 mg; 4 mg was the sweet spot.
• Duration: trials ran 28 days, with follow-up out to weeks; symptom and structural nerve changes were measurable by day 28.
• The half-life paradox: ARA-290 clears the blood in minutes, yet is dosed once daily and works. It triggers a downstream repair program rather than needing sustained blood levels, so the effect outlasts the drug by 24-72 hours. This is why a minutes-long half-life and once-daily dosing are not a contradiction.

The safety story is EPO's, inverted

The single most important safety fact: because ARA-290 works through the innate repair receptor and not the classic EPO receptor, it does not stimulate red-cell production or raise hematocrit — confirmed in the trials, with no change in hemoglobin, hematocrit, or reticulocytes.

That removes the clotting hazard that makes EPO dangerous and is the reason chronic dosing for repair is even conceivable. Across the Phase 2 trials the only adverse events were mild, transient injection-site reactions; no serious drug-related events. The honest limit: total human exposure is small (under ~200 patients, all ≤28 days), so long-term safety is uncharacterized, and as an innate-repair-receptor agonist it should be treated cautiously in active malignancy.

You probably can't get the real thing

This is the practical catch. ARA-290 was developed by Araim Pharmaceuticals, earned FDA Orphan Drug and Fast Track designations for sarcoidosis neuropathic pain plus EU orphan status, met its Phase 2b endpoint — and then stalled. No Phase 3 was completed, it is not approved for anything, and as of 2026 Araim has effectively ceased operations with no active trials registered. So there is no pharmaceutical supply. On the grey market it is far rarer and costlier than BPC-157 or TB-500, carried by few vendors intermittently, which means less independent testing and higher odds of an underdosed or degraded 11-amino-acid peptide. If someone sources it, a third-party HPLC-plus-mass-spec certificate per batch is non-negotiable.

What people report

Controlled trials are the evidence; user accounts are color. One first-person write-up describes going from weeks of stabbing nerve pain to none on ARA-290.

A single uncontrolled anecdote, weighed far below the randomized data — but it rhymes with what the trials measured.

Where it fits for the spine

In a disc-recovery stack the division of labor is clean. BPC-157 and TB-500 target the tissue — annulus, ligament, surrounding soft tissue. Retatrutide targets mechanical load. ARA-290 targets the nerve: it is the arm for the neuroinflammatory, radicular pain of a herniation, and the only one of the four with human evidence of actual nerve regeneration. The inflamed nerve root of a herniated disc is, mechanistically, exactly the small-fiber, neuroinflammatory target ARA-290 was built for — even though no one has run it against discs. The framework is in the disc-stack, herniated-disc, and degenerative-disc-disease pages.

Proven, unproven, unknown

Proven in humans: ARA-290 reduces neuropathic-pain symptoms and increases measurable nerve-fiber regrowth in sarcoidosis small-fiber neuropathy, and improves diabetic neuropathic symptoms — in randomized, placebo-controlled trials, without raising hematocrit. Unproven: that this translates to the radicular pain of a herniated disc; that step is mechanistic reasoning plus adjacent trial data, not a disc trial. Unknown: long-term safety, and — practically — whether the vial you can actually buy contains the real peptide.

Not medical advice. ARA-290 is investigational, not approved for any condition, and has no pharmaceutical supply. Nothing here is a dosing or treatment recommendation.